Epoxide electrophiles as activity-dependent cysteine protease profiling and discovery tools

Chemistry and Biology

Volumn 7, Issue 8, 2000, Pages 569-581

  Greenbaum, Doron ^a   Medzihradszky, Katalin F ^a   Burlingame, Alma ^a   Bogyo, Matthew ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Affinity labeling; Cysteine protease; E 64; Electrophile; Epoxide; Proteomics

Indexed keywords

CYSTEINE PROTEINASE; CYSTEINE PROTEINASE INHIBITOR; DCG 03; DCG 04; DRUG DERIVATIVE; EPOXIDE; JPM 565; LEUCINE; N [N (3 CARBOXYOXIRANE 2 CARBONYL)LEUCYL]AGMATINE; PEPTIDE; PEPTIDE LIBRARY; TUMOR PROTEIN;

AFFINITY LABELING; ANIMAL; ANTIBODY SPECIFICITY; ARTICLE; CELL CULTURE; CHEMISTRY; DENDRITIC CELL; DISEASE COURSE; ENZYME SPECIFICITY; ENZYMOLOGY; GENE EXPRESSION REGULATION; KIDNEY; METABOLISM; MOLECULAR PROBE; MOUSE; RAT; SKIN TUMOR; SYNTHESIS;

AFFINITY LABELS; ANIMALS; CYSTEINE ENDOPEPTIDASES; CYSTEINE PROTEINASE INHIBITORS; DENDRITIC CELLS; DISEASE PROGRESSION; EPOXY COMPOUNDS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; KIDNEY; LEUCINE; MICE; MOLECULAR PROBES; NEOPLASM PROTEINS; ORGAN SPECIFICITY; PEPTIDE LIBRARY; PEPTIDES; RATS; SKIN NEOPLASMS; SUBSTRATE SPECIFICITY; TUMOR CELLS, CULTURED;

ANIMALIA;

EID: 0033835372     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1074-5521(00)00014-4     Document Type: Article

References (52)

1. Microarrays: Biotechnology's discovery platform for functional genomics
2. Genomics and array technology
3. Proteomics in human disease: Cancer, heart and infectious diseases
4. Human and mouse proteomic databases: Novel resources in the protein universe
5. Correlation between protein and mRNA abundance in yeast
6. Structure of rat procathepsin B: Model for inhibition of cysteine protease activity by the proregion
7. Structure of human procathepsin L reveals the molecular basis of inhibition by the prosegment
8. Proteases involved in MHC class II antigen presentation
9. Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency
10. Prohormone and proneuropeptide processing. Recent progress and future challenges
11. Macrophage cathepsin L, a factor in the erosion of subchondral bone in rheumatoid arthritis
12. Cathepsin B and human tumor progression
13. Processing of the amyloid protein precursor to potentially amyloidogenic derivatives
14. Lysosomal processing of amyloid precursor protein to Aβ peptides: A distinct role for cathepsin S
15. Peptidyl diazomethanes as inhibitors of cysteine and serine proteinases
16. Peptidyl fluoromethyl ketones as thiol protease inhibitors
17. Comparative behaviour of calpain and cathepsin B toward peptidyl acyloxymethyl ketones, sulphonium methyl ketones and other potential inhibitors of cysteine proteinases
18. Potent and selective inactivation of cysteine proteinases with N-peptidyl-O-acyl hydroxylamines
19. Vinyl sulfones as mechanism-based cysteine protease inhibitors
20. L-trans-Epoxysuccinyl-leucylamido(4-guanidino)butane (E-64) and its analogues as inhibitors of cysteine proteinases including cathepsins B, H and L
21. Iodination of peptidyl chloromethyl ketones for protease affinity labels
22. Substrate binding and sequence preference of the proteasome revealed by active-site-directed affinity probes
23. Selective targeting of lysosomal cysteine proteases with radiolabeled electrophilic substrate analogs
24. The identification of active forms of cysteine proteinases in Kirsten-virus-transformed mouse fibroblasts by use of a specific radiolabeled inhibitor
25. 125l]iodotyrosylalanyidiazomethane as a probe for active cysteine proteinases in human tissues
26. Covalent modification of the active site threonine of proteasomal β subunits and the Escherichia coli homolog HsIV by a new class of inhibitors
27. Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo anti-inflammatory activity
28. Multiple species of CPP32 and Mch2 are the major active caspases present in apoptotic cells
29. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis
30. Methionine aminopeptidase (type 2) is the common target for angiogenesis inhibitors AGM-1470 and ovalicin
31. The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2
32. Activity-based protein profiling: The serine hydrolases
33. Structural basis of inhibition of cysteine proteases by E-64 and its derivatives
34. Mechanistic studies on the inactivation of papain by epoxysuccinyl inhibitors
35. Molecular cloning and expression of human aveolar macrophage cathepsin S, an elastinolytic cysteine protease
36. Novel epoxysuccinyl peptides. A selective inhibitor of cathepsin B, in vivo
37. Transgenic approaches to the analysis of ras and p53 function in multi-stage carcinogenesis
38. Role of oncogenes and tumor suppressor genes in multistage carcinogenesis
39. Human kidney cathepsins B and L. Characterization and potential role in degradation of glomerular basement membrane
40. Exocytosis of active cathepsin B enzyme activity at pH 7.0, inhibition and molecular mass
41. The identification of the major excreted protein (MEP) from a transformed mouse fibroblast cell line as a catalytically active precursor form of cathepsin L
42. Comparison of ras activation during epidermal carcinogenesis in vitro and in vivo
43. Presence of activated ras correlates with increased cysteine proteinase activities in human colorectal carcinomas
44. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
45. Tumor cell membrane cathepsin B
46. Revised definition of substrate binding sites of papain-like cysteine proteases
47. Distribution of cathepsins B and H in rat tissues and peripheral blood cells
48. Multiple processing of procathepsin L to cathepsin L in vivo
49. Genetic changes in skin tumor progression: Correlation between presence of a mutant ras gene and loss of heterozygosity on mouse chromosome 7
50. Loss of heterozygosity and mutational alterations of the p53 gene in skin tumours of interspecific hybrid mice
51. Loss of growth control by TGF-β occurs at a late stage of mouse skin carcinogenesis and is independent of ras gene activation